全文获取类型
收费全文 | 1077篇 |
免费 | 80篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 61篇 |
妇产科学 | 12篇 |
基础医学 | 95篇 |
口腔科学 | 48篇 |
临床医学 | 126篇 |
内科学 | 172篇 |
皮肤病学 | 13篇 |
神经病学 | 17篇 |
特种医学 | 258篇 |
外科学 | 173篇 |
综合类 | 70篇 |
预防医学 | 36篇 |
眼科学 | 4篇 |
药学 | 44篇 |
肿瘤学 | 54篇 |
出版年
2021年 | 5篇 |
2020年 | 1篇 |
2019年 | 8篇 |
2018年 | 17篇 |
2017年 | 7篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 17篇 |
2013年 | 9篇 |
2012年 | 9篇 |
2011年 | 16篇 |
2010年 | 40篇 |
2009年 | 25篇 |
2008年 | 15篇 |
2007年 | 38篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 21篇 |
2003年 | 36篇 |
2002年 | 32篇 |
2001年 | 31篇 |
2000年 | 18篇 |
1999年 | 23篇 |
1998年 | 64篇 |
1997年 | 76篇 |
1996年 | 78篇 |
1995年 | 50篇 |
1994年 | 40篇 |
1993年 | 47篇 |
1992年 | 23篇 |
1991年 | 26篇 |
1990年 | 21篇 |
1989年 | 45篇 |
1988年 | 44篇 |
1987年 | 35篇 |
1986年 | 35篇 |
1985年 | 39篇 |
1984年 | 13篇 |
1983年 | 11篇 |
1982年 | 13篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 6篇 |
1969年 | 1篇 |
1966年 | 1篇 |
1950年 | 1篇 |
排序方式: 共有1185条查询结果,搜索用时 13 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
3.
Sonoelasticity imaging of prostate cancer: in vitro results 总被引:2,自引:0,他引:2
4.
5.
6.
7.
8.
Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
9.
10.
Declan Donovan BSc Dr. Judith H. Harmey PhD Deirdre Toomey BSc D. Henry Osborne MCh H. Paul Redmond MCh David J. Bouchier-Hayes MCh 《Annals of surgical oncology》1997,4(8):621-627
Background: Angiogenesis is essential for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is the most potent angiogenic
factor identified to date. TGFβ-1 acts as an indirect angiogenic agent.
Methods: VEGF and TGFβ-1 were measured in the serum of breast cancer patients and agematched controls and in tumor tissue of cancer
patients by ELISA. VEGF protein and mRNA expression by breast tumor cell lines were examined, and the effect of TGFβ-1 on
VEGF production in these cells was assessed.
Results: VEGF levels were significantly higher (P=.03) in the serum of patients with breast cancer compared to age-matched controls. A positive correlation was found between
serum (r=0.539) and tumor tissue (r=0.688) levels of VEGF and TGFβ-1. Metastatic MDA-MB-231 breast cancer cells produce more
VEGF than do the primary BT474 cells. TGFβ-1 significantly (P<.05) increased production of VEGF.
Conclusions: Breast cancer cells constitutively produce VEGF protein and mRNA. There is a relationship between VEGF and TGFβ-1 levels
in breast cancer patients, and TGFβ-1 regulates VEGF expression by breast cancer cells.
Presented at the 50th Annual Cancer Symposium of the Society of Surgical Oncology, Chicago, Illinois, March 20–23, 1997. 相似文献